Unknown

Dataset Information

0

VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.


ABSTRACT: Blockading programmed death ligand 1 (PD-L1) shows promising results in patients with some cancers, but not in those with ovarian cancer. V-domain Ig suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint protein that suppresses T cell activation. This study aimed to investigate the expression and clinical significance of VISTA in ovarian cancer as well as its relationship with PD-L1. VISTA and PD-L1 levels in 146 ovarian cancer samples were assessed using immunohistochemistry. We investigated the association between VISTA and other clinicopathological variables, including survival. The associations between the VISTA-encoding C10orf54 gene, other immune checkpoints, and survival were analyzed. VISTA was detected in 51.4% of all samples and 46.6% of PD-L1-negative samples; it was expressed in 28.8%, 35.6%, and 4.1% of tumor cells (TCs), immune cells (ICs), and endothelial cells, respectively. Furthermore, VISTA expression was associated with pathologic type and PD-L1 expression. Moreover, VISTA expression in TCs, but not in ICs, was associated with prolonged progression-free and overall survival in patients with high-grade serous ovarian cancer. The expression of C10orf54 mRNA was associated with prolonged overall survival and immune escape-modulating genes. These results showed that VISTA expression in ovarian tumor cells was associated with a favorable prognosis in patients with high-grade serous ovarian cancer; however, additional studies are required to better understand the expression and role of VISTA in ovarian cancer.

SUBMITTER: Zong L 

PROVIDER: S-EPMC6949319 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.

Zong Liju L   Zhou Yuncan Y   Zhang Ming M   Chen Jie J   Xiang Yang Y  

Cancer immunology, immunotherapy : CII 20191128 1


Blockading programmed death ligand 1 (PD-L1) shows promising results in patients with some cancers, but not in those with ovarian cancer. V-domain Ig suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint protein that suppresses T cell activation. This study aimed to investigate the expression and clinical significance of VISTA in ovarian cancer as well as its relationship with PD-L1. VISTA and PD-L1 levels in 146 ovarian cancer samples were assessed using immunohisto  ...[more]

Similar Datasets

| S-EPMC7644024 | biostudies-literature
| S-EPMC3633976 | biostudies-literature
| S-EPMC8219231 | biostudies-literature
| S-EPMC7320055 | biostudies-literature
| S-EPMC5707051 | biostudies-other
| S-EPMC7484370 | biostudies-literature
2023-12-11 | GSE249935 | GEO
| S-EPMC7226362 | biostudies-literature
| S-EPMC7909685 | biostudies-literature
| S-EPMC6176182 | biostudies-other